Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

EU

MPs urge government to set out plans for post-Brexit medicines regulation

MPs have urged the government to set out its plans for regulatory functions currently delivered by the European Union (EU), including those relating to medicines safety, as soon as possible.

In its first report, the House of Commons’ Exiting the European Union Committee says it is up to the government to decide whether it wants the UK to remain part of EU-run regulatory agencies — including the European Medicines Agency (EMA) — after Brexit, adding that future relationships will need to be defined during negotiations.

The committee was set up to examine the expenditure, administration and policy of the Department for Exiting the European Union and public bodies.

The report, published on 14 January 2017, follows the committee’s inquiry into the UK government’s process for exiting the EU and its negotiating objectives.

“It will be essential to provide clarity as soon as possible, and certainly by the time the UK leaves the EU, about the government’s preferred option for the UK’s future participation in EU regulatory bodies,” the report says.

“If it is decided, however, not to seek to maintain membership of these bodies then the government must set out the new arrangements it proposes to put in place to ensure that these functions are carried out in future,” it adds.

The report and the need for clarity on the future of regulation was welcomed by the Association of the British Pharmaceutical Industry (ABPI), which gave evidence to the inquiry.

Mike Thompson, chief executive of the ABPI, says: “We are confident that government understands that any transitional arrangements should not put patient access to medicines under threat. We will continue to work with government to make sure this happens as smoothly as possible.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202198

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Houses of Parliament, London

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.